PONLIMSI Biosimilar Approval and Xolair Filings Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA) [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
FDA and EMA acceptance of its proposed Xolair (omalizumab) biosimilar filings. These moves deepen Teva's presence in higher-value biosimilars, reinforcing its Pivot to Growth plan and shifting more of its portfolio toward complex biopharmaceutical products. We'll now examine how the FDA approval of PONLIMSI, in particular, may reshape Teva's investment narrative and future earnings mix. Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Teva Pharmaceutical Industries Investment Narrative Recap To own Teva today, you need to believe its Pivot to Growth can gradually shift the story from low-growth generics toward higher-margin branded and biosimilar drugs, while its heavy US$15 billion-plus net debt burden keeps trending down. The PONLIMSI approval supports the near term growth narrative around complex biosimilars, but it does not remove the key risk
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) [Yahoo! Finance]Yahoo! Finance
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)GlobeNewswire
- Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After A Sharp One Month Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 [Yahoo! Finance]Yahoo! Finance
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026GlobeNewswire
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form ARS
- 3/31/26 - Form DEF
- TEVA's page on the SEC website